Please assess the completion status of the following clinical trial:

Trial Title: A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy~* Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash~* Baseline 24-hour average pain intensity score ≥ 4.0 based on an 11-point PI-NRS~* Provides written informed consent in accordance with all applicable regulatory requirements~Exclusion Criteria:~* Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:~* The pain is located at a different region of the body; and~* The pain intensity is not greater than the pain intensity of the PHN; and~* The subject can assess PHN pain independently of other pain~* Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study~* Hepatic impairment defined as ALT or AST \> 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin \> 1.5x ULN~* Chronic hepatitis B or C~* Impaired renal function defined as creatinine clearance \<60 mL/min or requiring hemodialysis~* Corrected QT (QTc) interval ≥ 450 msec or QTc interval ≥480 msec for patients with Bundle Branch Block~* Uncontrolled hypertension at screen (sitting systolic \>160 mmHg and/or sitting diastolic \>90 mmHg)~* Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs~* Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment~* Is considered to be clinically significant and may pose a safety concern, or,~* Could interfere with the accurate assessment of safety or efficacy, or,~* Could potentially affect a subject's safety or study outcome~* Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year~* Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication~* Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment~* History of clinically significant drug or alcohol abuse (DSM-IV-TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted.~* Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device~* Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:~* Within preceding month for studies unrelated to PHN, or~* Within preceding six months for studies related to PHN~* Treated previously with GEn~* History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo
- GEn 1200mg/day (Type: EXPERIMENTAL): gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
- GEn 2400mg/day (Type: EXPERIMENTAL): gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
- GEn 3600mg/day (Type: EXPERIMENTAL): gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).